Breakthrough for AlzeCure in the development of drugs for nerve pain
AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.
New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.
– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.
AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.
Limitless Potential: Winner of the Flemingsberg Science Award 2025
Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.
Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future
In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.
En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt
Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.
She’s Building Bridges Between People and Place – Meet Karin, the Placemaker Behind the Future of Flemingsberg
Karin Lekberg is paving the way for the Flemingsberg of the future, a place where knowledge and creativity meet. She envisions a vibrant area full of culture, evening and nightlife, and a natural meeting place for both students and creators. But when the goal feels far away, it’s about starting where you are, creating life and activity here and now, and above all, building on the stories that already exist, allowing the place to grow into its future.
Hon bygger broar mellan människor och plats – möt Karin, platsmäklaren bakom framtidens Flemingsberg
Karin Lekberg krattar vägen för framtidens Flemingsberg, platsen där kunskap och kreativitet möts. Hon vill skapa ett levande område med kultur, kvälls- och nattliv, och en naturlig plats för både studenter och kreatörer. Men när målet känns långt bort handlar det om att börja där man står, att skapa liv och aktiviteter här och nu, och inte minst bygga vidare på de berättelser som redan finns och låta platsen växa in i sin framtid.
